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A B S T R A C T
Cisplatin is a highly effective chemotherapeutic drug acting as a DNA-damaging agent that induces apoptosis of
rapidly proliferating cells. Unfortunately, cellular resistance still occurs. Mutations in p53 in a large fraction of
tumor cells contribute to defects in apoptotic pathways and drug resistance. To uncover new strategies to
eliminate tumors through a p53-independent pathway, we established a simplified model devoid of p53 to study
cisplatin-induced regulated cell death, using the yeast Saccharomyces cerevisiae. We previously showed that
cisplatin induces an active form of cell death accompanied by DNA condensation and fragmentation/degrada-
tion, but no significant mitochondrial dysfunction. We further demonstrated that proteasome inhibition, either
with MG132 or genetically, increased resistance to cisplatin. In this study, we sought to determine how pro-
teasome inhibition is important for cisplatin resistance by analyzing how it affects several phenotypes associated
with the DNA damage response. We found MG132 does not seem to affect the activation of the DNA damage
response or increase damage tolerance. Moreover, central modulators of the DNA damage response are not
required for cisplatin resistance imparted by MG132. These results suggest the proteasome is involved in
modulation of cisplatin toxicity downstream of DNA damage. Proteasome inhibitors can sensitize tumor cells to
cisplatin, but protect others from cisplatin-induced cell death. Elucidation of this mechanism will therefore aid in
the development of new strategies to increase the efficacy of chemotherapy.
1. Introduction
Cisplatin is one of the most widely used chemotherapeutic drugs,
due to its effectiveness against several types of tumors such as testi-
cular, ovarian, bladder, lung and head and neck cancers [1]. It is a
platinum-based compound that binds to DNA, leading to the formation
of intra- and interstrand crosslinks, which affects several cellular pro-
cesses, including DNA synthesis, RNA transcription and cell cycle pro-
gression [2]. When DNA repair mechanisms are unable to repair cis-
platin-induced DNA damage, cell death mechanisms are activated [3].
However, resistance to cisplatin still occurs, either intrinsic or acquired.
In order to increase efficacy and reduce toxicity to normal cells, com-
bination treatments with lower concentrations of different classes of
compounds that preferentially target tumor cells are desirable. Of these,
proteasome inhibitors appear as a promising strategy. Bortezomib was
the first inhibitor of the 26S proteasome approved for cancer treatment,
in patients with relapsed and refractory multiple myeloma, followed by
carfilzomib and others under development [4]. Clinical trials have also
addressed whether combining bortezomib with other chemother-
apeutics would be more effective, though results varied and fell short of
expectations [5]. However, there seemed to be little prior scientific
evidence regarding the effectiveness of the proposed treatment regi-
mens, since mechanistic aspects have been poorly characterized.
It has been shown that proteasome inhibitors can sensitize tumor
cells such as breast, bladder, ovarian, and head and neck squamous cell
carcinoma cells (HNSCC) to cisplatin, but protected cultured renal
tubular epithelial cells (RTEC) from cisplatin-induced apoptosis [6–10]
and attenuated cisplatin nephrotoxicity in vivo [11]. Proteasome in-
hibition also slightly sensitized breast cancer cells to 5-FU, multiple
myeloma cells to curcumin and doxorubicin, among others [12–15], but
protected neuroblastoma cells from taxol or vinblastine-induced apop-
tosis [16]. It was initially proposed that the effect of proteasome in-
hibitors is due to inhibition of NF-κB activation, leading to changes in
the expression of pro- and anti-apoptotic genes. However, this hy-
pothesis was later challenged, and therefore no single mechanism of
action is described [17] and a systematic characterization is lacking. In
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many cases, it appears that a functional p53 is fundamental for cis-
platin-induced cell death [18,19]. Yet, other studies found no correla-
tion between p53 status and cell death mediated by this drug under
different cellular contexts [20,21]. Since mutations in p53 are highly
frequent in most human cancers [22], we previously used yeast cells as
a model to elucidate p53-independent regulation of cell death induced
by cisplatin. We showed that cisplatin induces a mitochondria-in-
dependent regulated cell death (RCD) in budding yeast and that pro-
teasome inhibition, either genetically or pharmacologically, led to re-
sistance to this drug [23]. Since the mechanisms proposed to explain
the involvement of the proteasome in cisplatin-induced cell death in
human cell lines are either not present in yeast or would only explain
synergistic increased sensitivity, we concluded an unknown mechanism
underlies the observed phenotype. In the present study, we therefore
assessed the involvement of DNA damage and DNA damage repair in
the increased resistance of yeast cells to cisplatin imparted by protea-
some inhibition, in order to shed light into a conserved pathway
modulating cisplatin sensitivity that can be exploited in novel therapies.
2. Materials and methods
2.1. Growth conditions and treatments
Saccharomyces cerevisiae strains (Table 1) were grown overnight in
Synthetic complete medium (SC; 1.37 g/L Drop-Out mix, 1 g/L proline,
with 2% (w/v) glucose) at 30 °C and 200 rpm, diluted to OD 0.3 in the
same medium containing 0.003% SDS, and grown for an additional 3 h.
Afterwards, cells were treated with 118 μM MG132 (Sigma) or the
equivalent volume of DMSO for 30min. Then, cisplatin (30–300 μg/mL,
Sigma) resuspended in DMSO or 0.1% methyl methanesulfonate (MMS,
Fluka) was added to the cell cultures. In specific cases, after 3 h of
treatment, cells were washed, resuspended in fresh medium and in-
cubated at 30 °C, 200 rpm for an additional period of 24 h. Treatment
with 75 μg/mL of cycloheximide (CHX, Sigma) was used when in-
dicated. Though cisplatin was stored in aliquots in the dark and re-
suspended immediately prior to use, to minimize exposure to air, some
variability in cytotoxicity between independent experiments was un-
avoidable.
2.2. Viability assays
For semi-quantitative spot assays, cells were collected at specific
time points, and 5 μL of the cell suspensions and serial dilutions (10−1
to 10−4) were spotted on YPDA plates (1% yeast extract, 2% (w/v)
bactopeptone, 2% (w/v) glucose, 2% (w/v) agar), followed by in-
cubation for 2 days at 30 °C. Plates were then photographed using an
appropriate equipment.
2.3. Mutator assay
Fluctuation analysis [24] was used to determine frequencies of
CAN1 inactivation and hom3-10 reversion. Individual BF264-15D or
RDKY3615 mlh1Δ colonies that survived 100 μg/mL cisplatin treatment
(without or with MG132), as well as DMSO-treated control were grown
overnight in YPD, after which cells were washed, diluted in water, and
appropriate dilutions plated on complete media, SC-Glucose medium
lacking arginine containing 60 μg/mL canavanine (Sigma) and/or SC-
Glucose medium lacking threonine. After 2 days at 30 °C, colonies were
counted and mutation frequencies calculated as described [25].
2.4. Western blot
Protein samples from total cell extracts of wild type BF264-15D cells
treated with cisplatin or MMS were separated by SDS-PAGE (Sodium
dodecyl sulfate polyacrylamide gel electrophoresis) on a 12.5% poly-
acrylamide gel and transferred to a PVDF (polyvinylidene difluoride)
membrane. Then, membranes were incubated in 5% non-fat dry milk in
PBS-T (PBS solution with 0.1% Tween-20) for 1 h. For phosphorylated
H2A and Pgk1p detection, membranes were incubated overnight at 4 °C
with the primary antibodies anti-γH2AX (1:5000, Abcam) and anti-
PGK1 (1:5000, Molecular Probes), respectively. Incubations with anti-
rabbit (for γH2AX) and anti-mouse (for Pgk1p) secondary antibodies
(Jackson Laboratories) were performed at RT for 1 h.
Chemiluminescence detection of the bands was achieved using the ECL
system (GE Healthcare) and a Chemi-Doc XRS (BioRad).
2.5. Flow cytometry
For cell cycle analysis, cells were collected by centrifugation, wa-
shed with dH2O and the pellet was resuspended in 70% (v/v) ethanol.
After washing and resuspending the pellet in 50mM sodium citrate, pH
7.5, samples were incubated with 0.25mg/mL RNase A (Sigma) for 1 h
at 50 °C. Afterwards, 1 mg/mL Proteinase K (NZYtech) was added and
samples incubated 1 h at 50 °C. Sytox Green (Molecular Probes) diluted
in Tris-EDTA was added to a final concentration of 1 μM and samples
incubated overnight at 4 °C in the dark. Samples were sonicated (3
pulses, 1–3 s each) to avoid aggregates and analyzed in an Epics® XL™
flow cytometer (Beckman Coulter), with excitation and emission wa-
velengths of 490 nm and 520 nm, respectively (FL-1 channel). Data was
analyzed using FlowJo 7.6 software (Tree Star, Inc).
3. Results and discussion
3.1. The proteasome does not affect cisplatin-induced DNA damage
response
We have previously shown that inhibition of the proteasome results
in increased resistance of yeast cells to cisplatin [23] (also, see Fig. 4A).
Resistance to DNA damaging agents is usually attributed to decreased
intracellular availability of the drug, increased DNA repair, tolerance to
DNA lesions, or defective cell death induction downstream of DNA
damage, with the common result of failure to undergo cell death [26].
We first addressed whether inhibition of the proteasome could affect
DNA damage by monitoring phosphorylation of H2A. Like the H2AX
histone variant, H2A is phosphorylated in the presence of DNA double
strand breaks (DSBs) in response to several DNA damaging agents, one
of the first events signaling for the recruitment of DNA damage re-
sponse (DDR) factors and the repair of the DNA damage [27,28]. It is
important to highlight that cisplatin does not induce DSBs directly, but
these lesions may result from the processing of interstrand crosslinks.
We observed a clear increase in H2A phosphorylation after 3 h of
treatment with cisplatin or with the positive control MMS, an alkylating
agent known to induce DNA damage [29] (Fig. 1). These results are in
agreement with other studies, where an increase in phosphorylation
Table 1
S. cerevisiae strains used in this work.
Strain Genotype Source
BF264-15D MATa, leu2, trp1, ade1, his3 S. Reed
RDKY3615 MATa, ura3-52, leu2Δ1, trp1Δ63, his3-200,
lys2-Bgl, hom3-10, ade2Δ1, ade8,
YEL069C::URA3
R.Kolodner
mlh1Δ RDKY3615 mlh1::URA3 R.Kolodner
sml1Δ RDKY3615 sml1::KANmx4 R.Kolodner
sml1Δmec1Δ RDKY3615 sml1::KANmx4, mec1::HIS3 R.Kolodner
RDKY3023 MATa, ura3-52, leu2Δ1, trp1Δ63, his3-200,
lys2-Bgl, hom3-10, ade2Δ1, ade8
R.Kolodner
rad4Δ RDKY3023 rad4::URA3 R.Kolodner
W303 MATa, ade2-1, can1-100, his3-11,15, leu2-
3,112, trp1-1, ura3-1, RAD5+
X. Zhao
sgs1Δ W303 MATa, sgs1::HIS3 X. Zhao
rad51Δ W303 MATa, rad51::LEU2 X. Zhao
apn1Δ W303 MATalpha, apn1::KANmx4 X. Zhao
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levels of this protein was detected in yeast in response to DNA damage,
including exposure to MMS [30,31]. However, inhibition of the pro-
teolytic activity of the 26S proteasome complex with the peptide al-
dehyde MG132 (carbobenzoxy-Leu-Leu-leucinal) did not influence H2A
phosphorylation, since the phosphorylation levels were not sig-
nificantly different in the absence and presence of MG132. Finally, 24 h
after the removal of cisplatin from the medium, the phosphorylation
returned to basal levels, indicating recovery from damage of surviving
Fig. 1. The effect of proteasome inhibition on
H2A phosphorylation in response to cisplatin
treatment. Wild type BF264-15D cells were
treated with MG132 or DMSO for 30min fol-
lowed by incubation with cisplatin (100 μg/
mL) or MMS (0.1%) for 3 h. Afterwards, cells
were washed, ressupended in new medium and
cells collected after an additional 4 h and 24 h.
H2A phosphorylation levels were assessed by
Western Blot. Pgk1p levels were used as a
loading control.
Fig. 2. Resistance of DNA damage response-deficient mutants to cisplatin in the absence or presence of proteasome inhibition. The indicated mutant strains and
respective wild type controls were pre-incubated for 30min with MG132 or DMSO as indicated, followed by treatment with cisplatin for 3 h at 30 °C (2 h for rad4Δ
and respective wild type control). After exposure, cell viability was evaluated by spot assay on YPD plates. Spots of mutants and corresponding controls shown pair-
wise for experiments performed in parallel.
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cells. Taken together, these results indicate that MG132 does not reduce
cisplatin-induced DNA damage in yeast cells.
Next, we assessed if genes involved in DDR were required for the
observed phenotype. We chose genes coding for proteins involved in
cell cycle checkpoint (MEC1) and nucleotide excision repair, the major
pathway repairing cisplatin lesions (RAD4), as well as double strand
break repair (RAD51, SGS1); indeed mutants in these pathways were
shown to be sensitive to cisplatin [32]. In addition, since cisplatin can
also cause abasic sites to form [33], and the mismatch repair system is
involved in the processing of cisplatin adducts in mammalian cells [34],
we also chose the APN1 and MLH1 genes, respectively. Wild type
strains and mutants defective in cell cycle checkpoint (sml1Δmec1Δ and
respective sml1Δ control) and in the different DNA repair mechanisms
(rad4Δ, mlh1Δ, rad51Δ, sgs1Δ, apn1Δ) were pre-incubated for 30min
with MG132 or DMSO, followed by exposure to cisplatin for 3 h. Dif-
ferent cisplatin concentrations were tested according to the strain
sensitivity to the chemotherapeutic agent. Although the differential
sensitivities to cisplatin hamper a direct comparison of the extent of
protection afforded by MG132 in the different mutants, increased via-
bility in cells exposed to cisplatin in the presence of MG132 was always
observed, indicating that these particular genes are not required for this
process (Fig. 2).
3.2. The proteasome does not affect mutation frequencies of cisplatin-
treated cells
Since proteasome inhibition does not seem to affect the DNA da-
mage response following cisplatin exposure, we hypothesized that it
could lead to increased DNA damage tolerance (DDT). Through DDT,
DNA replication can bypass the lesions, allowing for later repair, al-
though it can be associated with increased mutagenesis (reviewed in
[35]). If this was the case, cells surviving exposure to cisplatin in the
presence of MG132 should have increased mutations over cells exposed
only to cisplatin. To test this hypothesis, we assessed the CAN1 in-
activation frequencies of wild type cells surviving exposure to 100 μg/
mL of cisplatin for 3 h, pre-treated with DMSO or MG132, and com-
pared it with those of cells treated with DMSO alone. As seen in Table 2,
there were no significant differences between the 3 conditions. We also
used mlh1Δ cells surviving the different treatments, in order better as-
sess whether MG132 affects mutation frequencies of cisplatin-treated
cells in a strain prone to mutations. For this purpose, we assessed CAN1
forward mutations as well as hom3-10 frameshifts in the RDKY3615
mlh1Δ reporter strain (Table 3). In accordance with a previous report
[36], exposure to cisplatin did not increase CAN1 inactivation fre-
quencies in mlh1Δ cells, and we found that it did not increase hom3-10
frameshifts. Moreover, exposure to MG132 had no effect on the fre-
quency of these mutations. Taken together, our results indicate that
increased resistance to cisplatin imparted by MG132 is not related with
a change in mutation frequency.
3.3. Proteasome inhibition does not affect cell cycle progression of cisplatin-
treated cells
After DNA damage induction, cell cycle arrest allows the cells to
repair these lesions and, afterwards, cell cycle progresses normally
[37]. Since the proteasome has a well-established role in the cell cycle
[38], we next evaluated whether MG132 affected cell cycle progression
of cisplatin-treated cells by flow cytometry. However, as seen in Fig. 3
proteasome inhibition had no effect on the cell cycle progression of
cisplatin-treated cells. Again, these results point to a role of the pro-
teasome in cisplatin-induced cell death independent of DNA damage.
3.4. MG132 does not protect cells from universal DNA damage-induced cell
death
In the previous sections, we show that no significant differences are
observed in DNA damage-associated phenotypes of cisplatin-treated
cells in the presence or absence of MG132, which indicates that the
proteasome is likely involved in the cell death mechanism. To assess the
specificity of this mechanism, we assessed whether MG132 also pro-
tected cells from death induced by a different DNA damaging agent.
Under our experimental conditions, we observed that MG132 does not
protect cells from death induced by MMS, unlike the clear increased
resistance to cisplatin (Fig. 4A). This is in agreement with another re-
port showing that proteasome inhibition only clearly protected cells
from chronic exposure to 4-Nitroquinoline 1-oxide (4-NQO), and had
minimal effects on cell death induced by 4-NQO or MMS [39]. Also,
differently from the case of cisplatin, MMS exposure did not lead to an
increased number of cells with sub G0/G1 DNA content (Fig. 4B), in-
dicative of DNA degradation during the cisplatin-induced cell death
process [40]. We also previously showed that inhibition of protein
biosynthesis increased the viability of yeast cells treated with cisplatin,
indicating that it induces an active form of cell death [23] (Fig. 4C).
However, we found that cycloheximide did not revert cell death in-
duced by MMS (Fig. 4C). Taken together, these results indicate that the
cell death processes induced by MMS and cisplatin are fundamentally
different and propose that MG132 functions by inhibiting an active
form of cell death induced by cisplatin, downstream of DNA damage.
Table 2





a Median frequencies of nine cultures. Values not statisti-
cally significant (Mann–Whitney test).
Table 3
Mutator phenotype of mlh1Δ cells.




a Median frequencies of nine cultures. Values not statistically significant
(Mann–Whitney test).
Fig. 3. The effect of proteasome inhibition on cell cycle progression of cisplatin-
treated cells. Wild type BF264-15D cells were treated with MG132 or DMSO for
30min, followed by exposure to cisplatin (100 μg/mL) for 3 h. Samples were
collected and, after staining with Sytox Green, fluorescence was measured by
flow cytometry. The percentage of cells in each phase of the cell cycle is re-
presented: G0/G1 (black), S (grey) and G2/M (light grey). Values represent
means and standard deviations of 3 independent experiments. * P < 0.05 cells
treated with cisplatin compared with the corresponding T0 (0 h); # P < 0.05,
## P < 0.01 cells treated with MG132 and cisplatin compared with the cor-
responding T0 (0 h).
A.R. Costa et al. DNA Repair 73 (2019) 28–33
31
4. Conclusions
Combination of cisplatin with other anticancer drugs is a promising
strategy to overcome cisplatin resistance. In particular, combinational
therapy with cisplatin and proteasome inhibitors proved to be effective
against several cancer cells lines. In contrast, proteasome inhibition
seemed to protect tubular renal cells and yeast cells from cisplatin-in-
duced cell death. The present study indicates the mechanisms under-
lying evasion from cisplatin-induced cell death imparted by proteasome
inhibitors occur downstream of DNA damage, and are amenable to
pharmacological modulation. Further elucidation of these pathways
will contribute towards strategies to preferentially sensitize tumor cells
Fig. 4. The effect of proteasome inhibition on cisplatin- or MMS-induced cell death. BF264-15D cells were grown in SC-Glu medium containing proline as nitrogen
source and 0.003% SDS for cell permeabilization. After 3 h, 118 μM of MG132 or the equivalent volume of DMSO was added to the medium for an additional period
of 30min. (A) Spot assay of cells treated with 100 μg/mL of cisplatin or 0.1% MMS for 180 min at 30 °C. (B) Sub G0/G1 DNA content of cells treated with 0.1% MMS.
Samples were collected at 0 h, 2 h, 3 h and after 4 h/24 h of MMS removal. After processing and staining with Sytox Green, fluorescence was measured by flow
cytometry. Values represent means and standard deviations of 3 independent experiments. (C) Spot assay of cells treated with 0.1% MMS or 100 μg/mL cDDP and
75 μg/mL of cycloheximide (CHX) for up to 180 min at 30 °C.
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to chemotherapy, both by increasing its efficacy and reducing its toxi-
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